Overslaan en naar de inhoud gaan

Pharming announces completion of acquisition of all North American commercialisation rights for RUCONEST® from Valeant

Operational updates

Pharming Group N.V. today announces that it has completed a definitive agreement to acquire all North American commercialisation rights for its own product, RUCONEST® (recombinant human C1 esterase inhibitor), including all rights in the US, Mexico and Canada, from certain subsidiaries of Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE/TSX: VRX).

Lees meer

Filters

  • Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren